作为帕金森病治疗策略的短链脂肪酸:神经退行症的影响
Abinash Ravi1, Suganiya Umapathy1, Ieshita Pan2
1Institute of Biotechnology, Department of Medical Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Thandalam, Chennai, Tamil Nadu, 602 105, India.
Cellular and molecular neurobiology
|October 22, 2025
概括
由肠道微生物产生的短链脂肪酸 (SCFA) 具有神经保护作用. 针对SCFA的策略可能为帕金森病 (PD) 等神经退行性疾病提供新的治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 微生物学 微生物学
- 胃肠病学 胃肠病学
背景情况:
- 神经退行,以帕金森病 (PD) 为例,涉及神经元损伤,缺乏有效的疾病修饰治疗.
- 肠-大脑轴受肠道微生物群代谢物,如短链脂肪酸 (SCFA) 的影响,越来越多地被认为是其在神经健康中的作用.
- 包括丁酸盐,酸盐和酸盐在内的SCFA对于维持肠道和神经平衡至关重要,具有抗炎和神经保护性质.
研究的目的:
- 探索SCFA在调节神经退行方面的机制性作用,特别关注帕金森病.
- 突出基于SCFA的策略作为神经退行性疾病的辅助疗法的潜力.
主要方法:
- 对调查肠-大脑轴和神经退行症中SCFA代谢的研究进行文献综述.
- 对SCFA的抗炎,神经保护和恒温功能的研究分析,特别是酸盐.
- 检查SCFA生产中断和PD进展之间的关联.
主要成果:
- SCFA是从食纤维发酵中产生的重要代谢物,对于肠道和神经平衡至关重要.
- SCFA具有有益的作用,包括抗炎症,维持血脑屏障的完整性和神经递质调节.
- 丁酸盐通过诸如HDAC抑制和线粒体支持等机制表现出显著的神经保护能力.
结论:
- SCFA 生产中断与神经退行性疾病 (如PD) 的进展有关.
- 基于SCFA的治疗策略有望恢复微生物平衡并减轻神经炎症.
- 通过SCFA向肠-大脑轴提供了一种新的多因素方法,以保护神经退行性疾病中的神经功能.
相关概念视频
01:24Parkinson's Disease: Treatment
972
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
972
01:15Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
01:37Neural Regulation
43.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.1K
01:29Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K
01:22Alzheimer's Disease: Treatment
811
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
811